Chemokines in neuroectodermal cancers: the crucial growth signal from the soil.

Détails

ID Serval
serval:BIB_81B6690AAE63
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Chemokines in neuroectodermal cancers: the crucial growth signal from the soil.
Périodique
Seminars in Cancer Biology
Auteur⸱e⸱s
Gross N., Meier R.
ISSN
1096-3650[electronic]
Statut éditorial
Publié
Date de publication
2009
Volume
19
Numéro
2
Pages
103-110
Langue
anglais
Résumé
Although chemokines and their receptors were initially identified as regulators of cell trafficking during inflammation and immune response, they have emerged as crucial players in all stages of tumor development, primary growth, migration, angiogenesis, and establishment as metastases in distant target organs. Neuroectodermal tumors regroup neoplasms originating from the embryonic neural crest cells, which display clinical and biological similarities. These tumors are highly malignant and rapidly progressing diseases that disseminate to similar target organs such as bone marrow, bone, liver and lungs. There is increasing evidence that interaction of several chemokine receptors with corresponding chemokine ligands are implicated in the growth and invasive characteristics of these tumors. In this review we summarize the current knowledge on the role of CXCL12 chemokine and its CXCR4 and CXCR7 receptors in the progression and survival of neuroectodermal tumors, with particular emphasis on neuroblastoma, the most typical and enigmatic neuroectodermal childhood tumor.
Mots-clé
Animals, Chemokine CXCL12/immunology, Chemokines/immunology, Humans, Neuroectodermal Tumors/immunology, Receptors, CXCR/immunology, Receptors, CXCR4/immunology, Receptors, Chemokine/immunology
Pubmed
Web of science
Création de la notice
27/06/2009 15:19
Dernière modification de la notice
20/08/2019 15:42
Données d'usage